Resources
11 Results (showing 1 - 10)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 3/25/2021 (updated 4/5/2024)
Recovery Housing, Medications for OUD (MOUD), and Emerging Issues
Presenters will explain recovery housing and MOUD in the context of issues emerging in rural America resulting from the pandemic and its impact on the rates of substance use disorder (SUD) and drug overdose. They will discuss the impact of the pandemic on the correctional system and state actions in response to COVID-19 as it affects those with SUD. They will also give an overview of how recovery housing can be developed, especially in rural areas.
Posted 8/4/2021 (updated 4/2/2024)
Posted 10/14/2021 (updated 4/3/2024)
Stimulant intoxication, withdrawal, and psychosis have accepted and established treatment strategies. Several lifesaving harm reduction interventions/services are available. There are no Food and Drug Administration-approved medications for treatment of stimulant use disorder, although several are promising. Behavioral treatment, especially the use of contingency management (and other approaches with supportive evidence), has by far the best evidence of effectiveness. The presenter reviewed topics of importance to clinicians treating individuals with stimulant use disorder.
Rick Rawson, PhD, University of Vermont Rural Center of Excellence
Posted 10/14/2021 (updated 4/3/2024)
Rural Community Opioid Response Program (RCORP) grantees discussed their efforts and initiatives working with criminal justice and corrections agencies to engage individuals who are incarcerated.
Posted 11/11/2021 (updated 4/3/2024)
This session presented resources and elements to consider when planning to collaborate with a local jail to establish pre- and post-release programing and coordination of care and services for individuals with SUD. A real-world example was presented by an RCORP grantee showcasing its First Day Forward Program.
Posted 6/7/2022 (updated 3/27/2024)
These presentations highlighted the efforts of two MAT Expansion grantees to collaborate with partners, including local community corrections entities.
Posted 3/21/2023 (updated 3/27/2024)
Training materials A Stimulating Talk
Posted 5/16/2023 (updated 3/27/2024)
Xylazine, a veterinary tranquilizer not approved for human use, has been increasingly identified in parts of the U.S. illicit drug supply.
Posted 7/26/2023 (updated 3/28/2024)
Just 5 years ago, only 1% of jails and prisons provided MOUD, but this practice has flourished. Dr. Costello discussed the emerging evidence base for MOUD in jails, regulatory changes, funding opportunities, and the dramatic increase in usage of MOUD in our nation's correctional facilities.
Posted 7/26/2023 (updated 3/28/2024)
This presentation provided an overview of the (1) current U.S. prevalence of opioid abuse and OUD and their societal consequences, (2) impacts of the opioid epidemic on rural geographic areas and populations, (3) recent emergence of synthetic opioids (e.g., fentanyl) and xylazine in the U.S. drug supply, and (4) most empirically supported treatment for patients with OUD.